GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
20.89
+0.50 (+2.45%)
At close: 11:24AM EDT
Stock chart is not supported by your current browser
Previous close20.39
Open20.35
Bid0.00 x 0
Ask0.00 x 0
Day's range20.35 - 20.89
52-week range18.14 - 21.20
Volume1,668
Avg. volume1,854
Market cap105.323B
Beta (3Y monthly)0.54
PE ratio (TTM)42.12
EPS (TTM)0.50
Earnings dateN/A
Forward dividend & yield0.95 (4.66%)
Ex-dividend date2019-05-16
1y target estN/A
Trade prices are not sourced from all markets
  • Reuters - UK Focus2 days ago

    Swiss agree to extradite Chinese scientist to U.S. on theft charges

    Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline. Gongda Xue, a 20-year Swiss resident, has been fighting extradition and was labelled a potential flight risk after he was detained by Swiss authorities earlier this year. The Swiss Federal Office of Justice confirmed on Wednesday that the U.S. request for his extradition was approved earlier this month, though Gongda Xue still has until mid-August to appeal to the Swiss Federal Criminal Court to block it.

  • GSK drug helps ovarian cancer patients live longer in late-stage study
    Reuters4 days ago

    GSK drug helps ovarian cancer patients live longer in late-stage study

    The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca. "Zejula's potential to expand PARP use beyond BRCAm (BRCA mutation) patients, was a key justification for its Tesaro acquisition and this required a positive outcome for Zejula in the PRIMA study," Jefferies analysts said.

  • Reuters - UK Focus4 days ago

    UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study

    GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.

  • GSK in talks to name HSBC's Symonds as its next chairman - Bloomberg
    Reuters5 days ago

    GSK in talks to name HSBC's Symonds as its next chairman - Bloomberg

    Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role. Citing people familiar with the talks, Bloomberg said the appointment could happen in the coming weeks.

  • GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg
    Reuters5 days ago

    GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg

    Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role. Citing people familiar with the talks, Bloomberg said the appointment could happen in the coming weeks.

  • Reuters - UK Focus5 days ago

    GSK in talks to name HSBC's Symonds as its next chairman- Bloomberg

    GlaxoSmithKline Plc is in talks to name HSBC's deputy chairman Jonathan Symonds as the next chairman of the British drugmaker, Bloomberg reported on Sunday, citing a person familiar with the matter. Symonds' appointment still needs to be finalised and is subject to approval from banking regulators, Bloomberg reported https://bloom.bg/2jSPkal. In January, the company said Chairman Philip Hampton would step down after more than three and a half years in the role.

  • GSK's two-drug HIV Dovato treatment meets main goal in study
    Reuters9 days ago

    GSK's two-drug HIV Dovato treatment meets main goal in study

    Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies. The study evaluated the effectiveness of Dovato in adults with the HIV-1 virus, who switched to the regimen from at least a triple combination containing Gilead's Vemlidy, the British company's HIV drugs division ViiV said.

  • Companies to Watch: T-Mobile joins S&P 500, Tesla to ramp up production, Marriott faces lawsuit
    Yahoo Finance9 days ago

    Companies to Watch: T-Mobile joins S&P 500, Tesla to ramp up production, Marriott faces lawsuit

    T-Mobile, Tesla, Marriott, GlaxoSmithKline, Pfizer and Caliva are the companies to watch.

  • Reuters - UK Focus9 days ago

    CORRECTED-UPDATE 2-GSK's two-drug HIV Dovato treatment meets main goal in study (July 10)

    GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday. Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market. Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.

  • Reuters - UK Focus9 days ago

    CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

    GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday. The study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults with the HIV-1 virus who switched to the regimen from at least a triple combination containing Gilead Sciences' Descovy, the British company's HIV drugs division ViiV said. The positive results further bolster GSK's efforts to challenge U.S. drugmaker Gilead, which currently leads the HIV treatment market.

  • Business Wire9 days ago

    ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen

    LONDON--(BUSINESSWIRE)-- ViiV Healthcare , the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from ...

  • Reuters11 days ago

    U.S. seeks extradition of Chinese researcher in drug secrets theft

    The United States wants Switzerland to extradite a Chinese researcher accused of helping his scientist sister steal secrets worth $550 million from drugmaker GlaxoSmithKline, Swiss documents released on Monday show. Gongda Xue, who is fighting extradition, has been labeled a potential flight risk, according to a Swiss Federal Criminal Court verdict, keeping him in custody pending the extradition request's resolution. U.S. allegations against Gongda Xue, 49, underscore global fears that China is using networks of highly trained nationals abroad to smuggle trade secrets to the world's second-largest economy.

  • Business Wire16 days ago

    ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

    Deborah Waterhouse, CEO, ViiV Healthcare, said: “For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals. With around 25,000 new HIV diagnoses in Europe* every year2, and the fact that today HIV is considered a chronic condition which requires people living with HIV (PLHIV) to remain on antiretroviral (ARV) treatment for life, it is ever more important to provide innovative treatment options.

  • GSK kicks off sale of $1.2 billion consumer health drugs: sources
    Reuterslast month

    GSK kicks off sale of $1.2 billion consumer health drugs: sources

    GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.

  • Reuters - UK Focuslast month

    GSK kicks off sale of $1.2 bln consumer health drugs -sources

    GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters. The drugmaker has bundled the non-core drugs into three different portfolios and has hired boutique investment bank Greenhill to market the products to separate bidders, said three sources familiar with the matter, speaking on condition of anonymity. Information packages for two portfolios consisting of Latin American drugs and Physiogel skin care products were sent out to prospective bidders earlier this week, the sources said.

  • GSK pharma head flags need for speed in high-pressure drug market
    Reuterslast month

    GSK pharma head flags need for speed in high-pressure drug market

    Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters. Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure.

  • Reuterslast month

    GSK signs up gene-editing pioneers in drug discovery alliance

    GlaxoSmithKline, Britain's largest drugmaker, will pay up to $67 million (52.88 million pounds) over a five-year period for the new Laboratory for Genomics Research, which will be jointly run with the University of California and led by researchers such as Jennifer Doudna, a co-inventor of the CRISPR gene-editing technology. New gene editing tools - with CRISPR/Cas9 as the most prominent example - have thrown the door wide open for rearranging the genetic code much more precisely and at lower costs than previously possible. The technology made headlines last year when a Chinese scientist caused outrage with a claim to have "gene-edited" babies, but CRISPR/Cas9 can also be used in medical and agricultural research without interfering with the human germline.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes